Novartis Gets FDA Approval for New Antibiotic; Medtronic Reduces Water and Energy Use; World Spa and Well Being Conference Opens in Bangkok - Health Minute for September 14, 2012
Novartis has received approval for its new powdered formulation for an inhaled cystic fibrosis therapy. The inhaled antibiotic was recommended to regulators for approval by an FDA advisory panel. Novartis’s previous delivery system earned sales of $300 million dollars last year.
Medtronic has announced a 34 percent reduction in water use and a 15 percent reduction in energy use since 2007 in its performance review for the fiscal year 2012. The reductions are part of the company’s progressive environmental stewardship program that promotes the health of its employees, customers, and communities. Medtronic was recently named to the Dow Jones Sustainability World Index, and has been on Corporate Responsibility magazine’s 100 Best Corporate Citizens List for the last three years.
The World Spa and Well Being Congress 2012 opens on September 16th in Bangkok, Thailand. The event will examine Asian spa standards and innovation within the industry. One-third of the world’s spa operators are located in Asia.
For more information on these and other stories, visit 3BLMedia.com.